D24AC00345
Cooperative Agreement
Overview
Grant Description
Columbia aims to revolutionize pharmacology by delivering a high resolution precision monitoring system that can be used in large populations to assess drug efficacy and in individuals to tailor optimal drug treatment.
Their grand vision is to enable the transformation of clinical therapeutics to dramatically enhance capabilities to manage disease, substantially improve therapeutic benefits to patients by delivering precision therapeutics, and maximize benefit to pharmaceutical suppliers through the ability to anticipate and reduce adverse therapeutic effects.
Specifically, the INDIPHARM team proposes to:
1) Automate the identification of thousands of FDA approved drugs, drug metabolites, chemicals that modify drug metabolism, and drug impurities.
2) Utilize and validate the mass spectrometry platform in highly phenotyped cohorts by merging pharmacogenomic and pharmacocexposomic data.
3) Deliver multi-modal network and artificial intelligence based models to predict drug efficacy by integrating large scale pharmacogenomic and pharmacocexposomic data.
4) Deliver a database software infrastructure to house chemical libraries that facilitate the identification of tens of thousands of drugs, chemicals, and metabolites.
5) Develop combined pharmacogenomic and pharmacocexposomic models for optimizing drug therapies in individuals and populations.
6) Scale the mass spectrometry platform for application to large population studies (greater than 100,000 participants) and for a range of clinical settings to ensure widespread access.
Together, these goals will lead to transformative changes in the therapeutic landscape, provide improved therapy to patients in an equitable manner, and help alleviate unnecessary human suffering.
Subrecipients are Brown University, Emory University, Public Health Emory University Medicine, Harvard, Jackson Laboratory, and Mayo Clinic.
Their grand vision is to enable the transformation of clinical therapeutics to dramatically enhance capabilities to manage disease, substantially improve therapeutic benefits to patients by delivering precision therapeutics, and maximize benefit to pharmaceutical suppliers through the ability to anticipate and reduce adverse therapeutic effects.
Specifically, the INDIPHARM team proposes to:
1) Automate the identification of thousands of FDA approved drugs, drug metabolites, chemicals that modify drug metabolism, and drug impurities.
2) Utilize and validate the mass spectrometry platform in highly phenotyped cohorts by merging pharmacogenomic and pharmacocexposomic data.
3) Deliver multi-modal network and artificial intelligence based models to predict drug efficacy by integrating large scale pharmacogenomic and pharmacocexposomic data.
4) Deliver a database software infrastructure to house chemical libraries that facilitate the identification of tens of thousands of drugs, chemicals, and metabolites.
5) Develop combined pharmacogenomic and pharmacocexposomic models for optimizing drug therapies in individuals and populations.
6) Scale the mass spectrometry platform for application to large population studies (greater than 100,000 participants) and for a range of clinical settings to ensure widespread access.
Together, these goals will lead to transformative changes in the therapeutic landscape, provide improved therapy to patients in an equitable manner, and help alleviate unnecessary human suffering.
Subrecipients are Brown University, Emory University, Public Health Emory University Medicine, Harvard, Jackson Laboratory, and Mayo Clinic.
Funding Goals
THE FOUR INITIAL FOCUS AREAS ARE(1) HEALTH SCIENCE FUTURES(2) SCALABLE SOLUTIONS(3) PROACTIVE HEALTH(4) RESILIENT SYSTEMS
Grant Program (CFDA)
Awarding / Funding Agency
Place of Performance
New York
United States
Geographic Scope
State-Wide
Related Opportunity
D-AQD-FA-24-008
The Trustees Of Columbia University In The City Of New York was awarded
Precision Pharmacology Monitoring System for Enhanced Drug Efficacy
Cooperative Agreement D24AC00345
worth $18,474,445
from Interior Business Center in September 2024 with work to be completed primarily in New York United States.
The grant
has a duration of 3 years and
was awarded through assistance program 93.384 ADVANCED RESEARCH PROJECTS AGENCY for HEALTH (ARPA-H).
Status
(Ongoing)
Last Modified 9/3/24
Period of Performance
9/11/24
Start Date
9/10/27
End Date
Funding Split
$18.5M
Federal Obligation
$0.0
Non-Federal Obligation
$18.5M
Total Obligated
Activity Timeline
Additional Detail
Award ID FAIN
D24AC00345
SAI Number
None
Award ID URI
None
Awardee Classifications
Private Institution Of Higher Education
Awarding Office
140D04 IBC ACQ SVCS DIRECTORATE (00004)
Funding Office
140D04 IBC ACQ SVCS DIRECTORATE (00004)
Awardee UEI
QHF5ZZ114M72
Awardee CAGE
3FHD3
Performance District
NY-13
Senators
Kirsten Gillibrand
Charles Schumer
Charles Schumer
Modified: 9/3/24